US 12,077,533 B2
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
Atli Thorarensen, Stow, MA (US); Matthew Frank Brown, Stonington, CT (US); Agustin Casimiro-Garcia, Concord, MA (US); Ye Che, Groton, CT (US); Jotham Wadsworth Coe, Niantic, CT (US); Mark Edward Flanagan, Gales Ferry, CT (US); Adam Matthew Gilbert, Guilford, CT (US); Matthew Merrill Hayward, Old Lyme, CT (US); Jonathan David Langille, Quaker Hill, CT (US); Justin Ian Montgomery, Ledyard, CT (US); Jean-Baptiste Telliez, Lexington, MA (US); Rayomand Jal Unwalla, Bedford, MA (US); and John I Trujillo, Ledyard, CT (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Aug. 4, 2021, as Appl. No. 17/393,463.
Application 15/446,500 is a division of application No. 14/559,294, filed on Dec. 3, 2014, granted, now 9,617,258, issued on Apr. 11, 2017.
Application 17/393,463 is a continuation of application No. 15/446,500, filed on Mar. 1, 2017, granted, now 11,111,242.
Claims priority of provisional application 61/912,074, filed on Dec. 5, 2013.
Prior Publication US 2023/0009153 A1, Jan. 12, 2023
Int. Cl. A61K 31/4523 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 498/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/4523 (2013.01); C07D 471/08 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 498/04 (2013.01)] 2 Claims
 
1. A method for treating alopecia by administering to a mammal in need a therapeutically effective amount of a compound having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, and wherein
R2 is selected from the group consisting of hydrogen, deuterium, C1-C6 linear or branched chain alkyl, C3-C6 cycloalkyl, C6-C10 aryl, monocyclic or bicyclic heteroaryl, comprising 5- and/or 6-membered rings, (aryl)C1-C6 linear or branched chain alkyl, (heteroaryl)C1-C6 linear or branched chain alkyl, (heterocyclic)C1-C6 linear or branched chain alkyl, (C1-C6 linear or branched chain alkyl)aryl, (C1-C6 linear or branched chain alkyl)heteroaryl, (C1-C6 linear or branched chain alkyl)heterocyclic, C1-C6 linear or branched chain perfluoroalkyl, C1-C6 linear or branched chain alkoxy, C1-C6 linear or branched chain perfluoroalkoxy, halogen, cyano, hydroxyl, amino, carboxy, aminocarbonyl, (C1-C6 linear or branched chain alkyl)aminocarbonylamino, (C1-C6 linear or branched chain alkyl)aminocarbonyl, —SOR12, —SO2R12, —NR13SO2R12, —SO2NR13R14, and —NR13SO2NR14R15; where said alkyl, aryl and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, cyano, alkylamino, dialkylamino, CF3, aminocarbonyl, (C1-C6 linear or branched chain alkyl)aminocarbonyl, and C3-C6 cycloalkyl;
R3 is selected from the group consisting of hydrogen, deuterium, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, halogen, and cyano;
Ra, Rb, Rc and Rd are independently selected from hydrogen, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, aryl, alkylaryl, (aryl)C1-C6 linear or branched chain alkyl, (heteroaryl)C1-C6 linear or branched chain alkyl, heteroaryl, halogen, cyano, hydroxyl, C1-C6 linear or branched chain alkoxy, amino, carboxy, aminocarbonyl, (heterocyclic)C1-C6 linear or branched chain alkyl, (C1-C6 linear or branched chain alkyl)aryl, (C1-C6 linear or branched chain alkyl)heteroaryl, and (C1-C6 linear or branched chain alkyl)heterocyclic, where said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, alkylamino, dialkylamino, CF3, and C3-C6 cycloalkyl;
R0, R1, R4, R6, R8, R9 and R10 are independently selected from hydrogen, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, C6-C10 aryl, monocyclic or bicyclic heteroaryl, comprising 5- and/or 6-membered rings, (aryl)C1-C6 linear or branched chain alkyl, (heteroaryl)C1-C6 linear or branched chain alkyl, heteroaryl, halogen, cyano, hydroxyl, C1-C6 linear or branched chain alkoxy, amino, carboxy, aminocarbonyl, (heterocyclic)C1-C6 linear or branched chain alkyl, (C1-C6 linear or branched chain alkyl)aryl, (C1-C6 linear or branched chain alkyl)heteroaryl, and (C1-C6 linear or branched chain alkyl)heterocyclic, where said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, alkylamino, dialkylamino, CF3, and C3-C6 cycloalkyl; where, alternatively, R0 or R1, and/or R6, respectively together with either of R4, Ra, Rb, Rc or Rd, may independently form a bond or a C1-C6 linear alkyl chain; and/or, alternatively, R4, respectively together with either of Ra, Rb, Rc or Rd, may independently form a bond or a C1-C6 linear alkyl chain; and/or, alternatively, R8 and R9 may together form a 3-6-membered ring optionally containing one or two O or N atoms;
R11 is hydrogen or deuterium; and,
R12, R13, R14 and R15 are independently selected from hydrogen, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, C6-C10 aryl, alkylaryl, and (aryl)C1-C6 linear or branched chain alkyl.